import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "where-to-buy-ara-290-research-guide",
  title: "Where to Buy ARA-290: A Researcher's Sourcing Guide",
  description:
    "What researchers need to know before sourcing ARA-290 (cibinetide) — purity standards for this EPO-derived neuroprotective peptide, COA requirements, synthesis complexity, and how to evaluate research-grade supply.",
  category: "Quality & Testing",
  readMinutes: 9,
  publishedAt: "2026-06-18",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "ARA-290, also known as cibinetide, is an 11-amino acid peptide derived from a non-hematopoietic region of erythropoietin (EPO). Its sequence — CTGQKTICSIH (with an internal disulfide bond) — selectively activates the innate repair receptor (IRR), also identified as a β-common receptor (βCR) heterodimer, rather than the classical erythropoietin receptor (EPOR). This selectivity is what makes ARA-290 scientifically distinctive: it retains EPO's cytoprotective and anti-inflammatory signaling while eliminating the hematopoietic and thrombotic effects that have limited clinical application of EPO itself.",
    },
    {
      type: "paragraph",
      text: "The research literature on ARA-290 has expanded substantially, with studies covering neuropathic pain models, peripheral nerve repair, diabetes-associated small fiber neuropathy, and inflammatory pathway modulation. For researchers working in these areas, sourcing quality is non-negotiable — and ARA-290's structural complexity makes quality assessment more demanding than for linear peptides.",
    },
    {
      type: "heading",
      text: "ARA-290's Chemistry and Synthesis Complexity",
    },
    {
      type: "paragraph",
      text: "ARA-290's 11-residue sequence contains two cysteine residues that form an intramolecular disulfide bond (Cys1–Cys8 in the truncated peptide). This disulfide bridge is structurally critical — it constrains the peptide's conformation and is required for correct IRR binding. Linear ARA-290 (without the disulfide) is biologically inactive, making disulfide formation during synthesis a key quality control checkpoint.",
    },
    {
      type: "paragraph",
      text: "Forming a defined intramolecular disulfide bond requires controlled oxidation conditions during synthesis. Vendors producing ARA-290 without proper disulfide bond formation protocols will yield a mixture of linear peptide, intramolecular disulfide (correct), and intermolecular disulfide dimers (incorrect). These species can co-elute on standard HPLC, making a 98% purity reading misleading if the disulfide status is not separately verified by mass spectrometry under non-reducing conditions.",
    },
    {
      type: "heading",
      text: "Purity Standards for ARA-290 Research",
    },
    {
      type: "paragraph",
      text: "The accepted research-grade minimum for ARA-290 is ≥98% HPLC purity with confirmed disulfide bond formation by mass spectrometry. Given the biological inactivity of the linear form, a purity certificate without MS confirmation of the correct molecular weight (1316.5 Da for the disulfide-containing species, consistent with loss of 2 hydrogen atoms from free cysteines) provides incomplete quality assurance.",
    },
    {
      type: "paragraph",
      text: "Researchers should request both the HPLC trace and the ESI-MS or MALDI-MS spectrum. Under standard (non-reducing) MS conditions, the correct ARA-290 should show a molecular ion at m/z consistent with 1316.5 Da, not the reduced form at 1318.5 Da. A difference of 2 Da distinguishes active from inactive material — mass spectrometry at adequate resolution is the only way to confirm this.",
    },
    {
      type: "heading",
      text: "What a Complete ARA-290 COA Should Include",
    },
    {
      type: "list",
      items: [
        "HPLC chromatogram with retention time, peak area percentage, and mobile phase conditions (gradient, column type, wavelength)",
        "Mass spectrometry data confirming MW 1316.5 Da under non-reducing conditions — verifying intramolecular disulfide bond formation",
        "Amino acid analysis or sequence confirmation verifying the 11-residue sequence CTGQKTICSIH",
        "Appearance: white to off-white lyophilized powder",
        "Moisture content by Karl Fischer titration — allows calculation of true peptide content vs. label weight",
        "Endotoxin testing (LAL method, <1.0 EU/mg) for in vivo research applications",
        "Third-party laboratory letterhead — independent verification, not vendor internal testing",
        "Lot number with date of synthesis for batch traceability",
      ],
    },
    {
      type: "heading",
      text: "The Neuropathy Research Context: Why Structure Matters",
    },
    {
      type: "paragraph",
      text: "ARA-290's most clinically relevant research applications involve small fiber neuropathy, particularly in the context of diabetic and sarcoidosis-associated neuropathy. The published human trials — particularly work by Brines et al. and the Leiden University group — have used pharmaceutical-grade ARA-290 with defined disulfide bond status. Reproducing these findings with improperly folded peptide will yield false negatives, and published reproducibility failures of this type have set entire research areas back by years.",
    },
    {
      type: "paragraph",
      text: "The IRR's β-common receptor component is expressed in peripheral nervous tissue, corneal nerve fibers, and immune cells. ARA-290's documented effects in intraepidermal nerve fiber density (IENFD) restoration models depend on correct receptor engagement — which requires correct disulfide-mediated conformation. Researchers using confocal microscopy and punch biopsy IENFD quantification need a compound that actually activates the receptor, not a linear sequence lookalike.",
    },
    {
      type: "heading",
      text: "Stability and Handling for ARA-290",
    },
    {
      type: "paragraph",
      text: "ARA-290 in lyophilized form is stable at -20°C for up to 24 months in sealed, inert-atmosphere vials. The disulfide bond is susceptible to reduction under oxidizing/reducing agents and at elevated temperatures. Storage with oxygen scavengers (nitrogen or argon headspace) extends shelf life. Vials should be stored away from light to prevent phototoxic modification of the aromatic residues (His11 in particular).",
    },
    {
      type: "paragraph",
      text: "For reconstitution, sterile water (pH ~6–7) is preferred. ARA-290 is moderately soluble at 1–2 mg/mL. Avoid phosphate-buffered saline at high concentrations due to possible aggregation. Once reconstituted, store at 4°C and use within 2–3 weeks; do not subject to repeated freeze-thaw cycles, which can scramble the disulfide bond under the mechanical stress of ice crystal formation.",
    },
    {
      type: "heading",
      text: "Red Flags in the ARA-290 Supply Market",
    },
    {
      type: "list",
      items: [
        "COA without mass spectrometry data — the disulfide bond cannot be confirmed by HPLC alone",
        "Molecular weight reported as 1318.5 Da (reduced, linear form) rather than 1316.5 Da (disulfide-containing, active form)",
        "No mention of disulfide bond formation in synthesis documentation — suggests linear peptide synthesis without oxidative cyclization step",
        "Purity stated as a range without a specific measured value from a named third-party lab",
        "Prices significantly below market — ARA-290 synthesis requires controlled disulfide chemistry and high raw material quality; deep discounting suggests quality shortcuts",
        "Vials shipped at ambient temperature — the disulfide bond is stable at room temperature short-term, but cold-chain shipping is standard practice for high-value research peptides",
      ],
    },
    {
      type: "heading",
      text: "Why Nexphoria",
    },
    {
      type: "paragraph",
      text: "Nexphoria's ARA-290 is synthesized using controlled disulfide oxidation protocols, with HPLC purity ≥99% and mass spectrometry confirmation of the 1316.5 Da molecular weight on every production lot. Our COAs include the full MS spectrum — not just a stated value — so researchers can verify disulfide bond integrity independently. Third-party laboratory documentation covers every lot, and cold-pack shipping is standard on all orders.",
    },
    {
      type: "paragraph",
      text: "For researchers investigating small fiber neuropathy, peripheral nerve repair, or IRR-mediated cytoprotection, the structural correctness of ARA-290 is not an abstract quality concern — it determines whether your study will replicate published findings or produce noise. We've built our synthesis process around getting the disulfide right, every time.",
    },
    {
      type: "disclaimer",
      text: "ARA-290 (cibinetide) is sold by Nexphoria strictly for in vitro and preclinical research use. It is not approved for human consumption, therapeutic use, or veterinary application. All purchases require agreement to our research-use-only terms.",
    },
  ],
};
